Honest reviews of 89+ online health providers across GLP-1 weight loss, TRT, ED, hair loss, women's health, longevity, peptides, and primary care. Compare pricing, clinical oversight, and real patient experiences.
From week 20 to week 68, continued semaglutide produced 7.9% further average weight loss; switching to placebo was associated with 6.9% average weight gain.
803 adults with obesity or overweight plus a weight-related condition, without diabetes, who completed a 20-week semaglutide 2.4 mg lead-in; 68 weeks total; 48-week randomized period. Read the linked peer-reviewed source for the full methodology, findings, and limitations.
Rubino et al., JAMA 2021 · STEP 4